KBC Group
DFTX

KBC Group’s Definium Therapeutics DFTX Stock Holding History

KBC Group’s Portfolio DFTX Stock Details DFTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$41K Buy
+2,172
New +$36.9K ﹤0.01% 1722

Other funds holding DFTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.12B AUM 144% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
CC
Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

KBC Group's DFTX Position: Q1 2026 in Review

KBC Group opened a new position in Definium Therapeutics (DFTX) in Q1 2026: 2,172 shares worth $41K. The stake represents ﹤0.01% of the portfolio and ranks #1722 among its holdings.

247 funds tracked by Wall St. Rank hold DFTX as of Q1 2026.

  • KBC Group held 2,172 shares of Definium Therapeutics worth $41K as of Q1 2026.
  • Definium Therapeutics was a new KBC Group position in Q1 2026.
  • Definium Therapeutics made up ﹤0.01% of KBC Group's portfolio in Q1 2026, its #1722 holding.
  • 247 funds tracked by Wall St. Rank held Definium Therapeutics as of Q1 2026.

Based on KBC Group's 13F filing for Q1 2026, filed 7 May 2026.